Profile data is unavailable for this security.
About the company
Enovis Corporation is a medical technology company. It is focused on developing clinically differentiated solutions by manufacturing and distributing medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. It operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment develops, manufactures, and distributes rigid bracing products, orthopedic soft goods, vascular systems and compression garments, and hot and cold therapy products and offers recovery sciences products in the clinical rehabilitation and sports medicine markets, such as bone growth stimulators and electrical stimulators used for pain management. The Reconstructive segment develops, manufactures, and markets a variety of knee, hip, shoulder, elbow, foot, ankle, and finger implant products and surgical productivity tools. It also provides Novastep, a minimally invasive surgery (MIS) foot and ankle solutions.
- Revenue in USD (TTM)1.82bn
- Net income in USD-103.33m
- Incorporated1998
- Employees6.55k
- LocationEnovis Corp2711 CENTERVILLE ROAD, SUITE 400WILMINGTON 19808United StatesUSA
- Phone+1 (302) 252-9160
- Fax+1 (301) 323-9001
- Websitehttps://www.enovis.com/
More ▼
Mergers & acquisitions
| Acquired company | ENOV:NYQ since announced | Transaction value |
|---|---|---|
| Limacorporate SpA | -2.10% | 852.16m |
Data delayed at least 15 minutes, as of May 23 2024 16:47 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LeMaitre Vascular Inc | 199.89m | 33.95m | 1.80bn | 614.00 | 53.02 | 5.82 | 41.29 | 8.99 | 1.51 | 1.51 | 8.89 | 13.74 | 0.5977 | 1.17 | 7.19 | 325,548.90 | 10.15 | 9.02 | 10.99 | 9.93 | 66.45 | 65.83 | 16.99 | 15.45 | 5.31 | -- | 0.00 | 40.41 | 19.69 | 12.88 | 45.89 | 5.96 | 18.93 | 15.51 |
| UFP Technologies Inc | 407.33m | 47.88m | 1.94bn | 3.09k | 40.66 | 6.56 | 32.53 | 4.75 | 6.21 | 6.21 | 52.82 | 38.46 | 1.02 | 4.50 | 6.71 | 131,693.20 | 11.99 | 9.69 | 13.80 | 10.95 | 27.89 | 26.33 | 11.75 | 10.14 | 1.46 | 17.87 | 0.1039 | 0.00 | 13.08 | 16.00 | 7.50 | 25.71 | 14.08 | -- |
| Warby Parker Inc | 697.80m | -55.06m | 2.00bn | 2.14k | -- | 6.33 | -- | 2.87 | -0.467 | -0.467 | 5.91 | 2.66 | 1.21 | 5.19 | 655.52 | 326,074.80 | -9.57 | -- | -11.95 | -- | 55.01 | 57.49 | -7.89 | -14.53 | 2.02 | -- | 0.00 | -- | 11.98 | 19.67 | 42.75 | -- | -- | -- |
| Premier Inc | 1.34bn | 80.33m | 2.03bn | 2.80k | 30.09 | 1.05 | 10.29 | 1.52 | 0.6421 | 0.6421 | 11.34 | 18.35 | 0.3887 | 5.25 | 3.10 | 477,306.10 | 1.89 | 10.39 | 2.48 | 13.00 | 66.20 | 62.04 | 4.87 | 22.60 | 0.8226 | 143.62 | 0.276 | 19.11 | -6.76 | 2.44 | -34.17 | -15.30 | -2.29 | -- |
| STAAR Surgical Co | 326.24m | 15.30m | 2.09bn | 1.06k | 137.56 | 5.32 | 101.01 | 6.41 | 0.3093 | 0.3093 | 6.62 | 8.00 | 0.7159 | 2.11 | 5.09 | 308,942.30 | 3.36 | 6.77 | 3.82 | 7.90 | 78.51 | 76.89 | 4.69 | 9.16 | 5.22 | -- | 0.0004 | 0.00 | 13.37 | 21.07 | -46.18 | 33.85 | 51.95 | -- |
| Patterson Companies, Inc. | 6.57bn | 193.86m | 2.19bn | 7.60k | 12.07 | 2.27 | 7.83 | 0.334 | 2.03 | 2.03 | 68.86 | 10.78 | 2.23 | 5.61 | 14.48 | 864,047.90 | 6.58 | 0.3702 | 11.30 | 0.5655 | 21.30 | 21.05 | 2.95 | 0.1811 | 0.7243 | 12.08 | 0.4462 | 846.10 | -0.4298 | 3.44 | 2.14 | 10.79 | 8.22 | 0.00 |
| Conmed Corp | 1.26bn | 82.35m | 2.31bn | 4.00k | 28.60 | 2.70 | 14.96 | 1.83 | 2.62 | 2.62 | 40.12 | 27.76 | 0.545 | 1.73 | 5.55 | 315,387.00 | 3.56 | 0.8972 | 4.10 | 1.02 | 54.92 | 54.95 | 6.53 | 1.65 | 1.08 | 3.65 | 0.5369 | 139.16 | 19.06 | 7.68 | 179.99 | 10.04 | 2.89 | 0.00 |
| Helen of Troy Limited | 2.01bn | 168.59m | 2.52bn | 1.93k | 15.02 | 1.54 | 11.46 | 1.26 | 7.05 | 7.05 | 83.65 | 68.94 | 0.6971 | 2.48 | 5.19 | 1,040,503.00 | 5.86 | 7.69 | 6.90 | 9.53 | 47.31 | 44.32 | 8.41 | 9.24 | 0.9936 | 5.27 | 0.289 | -- | -3.26 | 5.09 | 17.67 | -0.6548 | 6.79 | -- |
| ICU Medical Inc | 2.26bn | -59.31m | 2.57bn | 14.00k | -- | 1.24 | 15.10 | 1.14 | -2.46 | -2.46 | 93.27 | 84.87 | 0.5154 | 2.12 | 15.86 | 161,223.70 | -1.35 | 1.46 | -1.51 | 1.65 | 32.48 | 34.11 | -2.63 | 2.23 | 1.09 | 0.4817 | 0.4393 | 0.00 | -0.9154 | 10.04 | 60.08 | -- | -1.45 | -- |
| Inari Medical Inc | 520.66m | -23.62m | 2.77bn | 1.30k | -- | 6.18 | -- | 5.32 | -0.409 | -0.409 | 8.95 | 7.71 | 0.8913 | 1.58 | 7.75 | 400,506.90 | -4.04 | -0.5941 | -4.57 | -0.6696 | 87.67 | 89.06 | -4.54 | -0.6295 | 2.19 | -- | 0.00 | -- | 28.73 | 135.40 | 94.41 | -- | 52.46 | -- |
| Enovis Corp | 1.82bn | -103.33m | 2.80bn | 6.55k | -- | 0.846 | 20.63 | 1.54 | -1.89 | -1.50 | 33.29 | 60.33 | 0.3717 | 1.49 | 5.49 | 277,452.20 | -2.10 | -0.3569 | -2.32 | -0.41 | 58.12 | 48.19 | -5.66 | -1.06 | 1.03 | 0.9243 | 0.2879 | -- | 9.22 | -4.89 | -40.29 | -- | 11.91 | -- |
| Envista Holdings Corp | 2.56bn | -120.40m | 3.20bn | 12.80k | -- | 0.7735 | 293.74 | 1.25 | -0.713 | -0.713 | 14.72 | 24.09 | 0.3904 | 3.89 | 6.29 | 200,226.60 | -1.83 | 1.94 | -2.15 | 2.34 | 56.35 | 57.65 | -4.70 | 5.29 | 1.93 | 5.09 | 0.2667 | 0.00 | -0.1012 | -2.04 | -142.10 | -- | -4.22 | -- |
| LivaNova PLC | 1.19bn | -31.77m | 3.28bn | 2.90k | -- | 2.68 | 194.90 | 2.77 | -0.5911 | -0.5911 | 21.89 | 22.56 | 0.4985 | 2.57 | 6.11 | 408,634.10 | -1.33 | -6.01 | -1.54 | -7.42 | 67.89 | 66.99 | -2.67 | -13.56 | 2.71 | 2.52 | 0.3383 | -- | 12.89 | 0.8278 | 120.34 | -- | -1.64 | -- |
| Tandem Diabetes Care Inc | 770.01m | -141.45m | 3.32bn | 2.40k | -- | 13.65 | -- | 4.31 | -2.17 | -2.17 | 11.82 | 3.76 | 0.8126 | 2.74 | 8.35 | 320,837.10 | -14.93 | -10.08 | -18.48 | -12.23 | 49.28 | 51.77 | -18.37 | -11.59 | 3.01 | -- | 0.5884 | -- | -6.68 | 32.39 | -135.33 | -- | 76.81 | -- |
| Procept Biorobotics Corp | 156.33m | -103.37m | 3.45bn | 626.00 | -- | 13.05 | -- | 22.06 | -2.12 | -2.12 | 3.20 | 5.14 | 0.4685 | 1.81 | 4.08 | 249,722.00 | -30.98 | -- | -34.68 | -- | 53.47 | -- | -66.12 | -- | 7.44 | -- | 0.1629 | -- | 81.55 | -- | -21.51 | -- | -- | -- |
| Axonics Inc | 387.14m | -15.95m | 3.45bn | 797.00 | -- | 5.50 | -- | 8.91 | -0.3134 | -0.3134 | 7.76 | 12.29 | 0.5606 | 1.20 | 8.53 | 485,744.00 | -2.31 | -12.67 | -2.52 | -13.76 | 75.25 | 70.04 | -4.12 | -29.68 | 8.04 | -- | 0.00 | -- | 33.86 | 249.06 | 89.80 | -- | 23.65 | -- |
Data as of May 23 2024. Currency figures normalised to Enovis Corp's reporting currency: US Dollar USD
57.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price Investment Management, Inc.as of 31 Mar 2024 | 6.59m | 12.06% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 4.83m | 8.84% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 4.48m | 8.21% |
| Dimensional Fund Advisors LPas of 31 Mar 2024 | 3.19m | 5.85% |
| Diamond Hill Capital Management, Inc.as of 31 Mar 2024 | 2.43m | 4.46% |
| Millennium Management LLCas of 31 Mar 2024 | 2.19m | 4.01% |
| Select Equity Group LPas of 31 Mar 2024 | 2.05m | 3.75% |
| Davenport & Co. LLCas of 31 Mar 2024 | 1.98m | 3.63% |
| Thrivent Asset Management LLCas of 31 Mar 2024 | 1.82m | 3.34% |
| Royce & Associates LPas of 31 Mar 2024 | 1.60m | 2.93% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
